Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· July 22, 2026
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
View original at finance.yahoo.comIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study MIAMI, July 22, 2026--(BUSINESS WIRE)--Summit Th…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
More detailed data from the June 2026 analysis are intended to be presented at an upcoming medical meeting.
60% confidenceThe study demonstrated a statistically significant benefit in the primary analysis for progression-free survival (PFS), one of the study's two primary endpoints along with OS.
60% confidenceA hazard ratio of 0.76 was observed in both the full intention-to-treat population and the subgroup of western patients as of the June 2026 data cut-off.
60% confidenceIvonescimab plus platinum-doublet chemotherapy continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone.
60% confidence
Cited in these Via News reports
- AI-Designed Biologics and Personalized mRNA Vaccines: What the Oncology Evidence Supports, and What It Doesn't →
- AstraZeneca Says Its Data Will Train Better Cancer Drugs. Its Pitch Rests on a Source That Failed Our Check. →
- AstraZeneca's AI 'Lab of the Future' Meets a Crowded Oncology Pipeline: What Is Proven, and What Is Still a Promise →
- AstraZeneca's AI Drug-Design Vision Is Still a Forecast, While Oncology's Near-Term Catalysts Are Conventional →
- AstraZeneca's AI-Designed-Biologics Pitch Is a Forecast, Not a Result: What the Oncology Pipeline Actually Shows →
- AstraZeneca's AI-to-Lab Loop Meets a Crowded Oncology Calendar, and the Evidence for It Is Still Thin →
- Oncology's Q4 Catalyst Season Meets Pharma's AI Pitch: What Is Verified, and What Is Still a Claim →
